Symptom profile in partial responders to a proton pump inhibitor compared with treatment-naïve patients with gastroesophageal reflux disease: a post hoc analysis of two study populations

BMC Gastroenterology

Anna Rydén¹  Hans Denison¹  Anna Niklasson¹  Nimish Vakil² 

[1] AstraZeneca R&D, Mölndal, Sweden;University of Wisconsin School of Medicine and Public Health, Aurora Summit Hospital, 36500 Aurora Drive, Summit WI 53066, USA

关键词: Gastric;    Regurgitation;    Proton pump inhibitors;    Heartburn;    Constipation;    Abdominal pain;   

Others  :  1121785
DOI  :  10.1186/1471-230X-14-177

 received in 2014-05-01, accepted in 2014-07-28,  发布年份 2014

【 摘 要 】

Background

Partial response to proton pump inhibitor (PPI) therapy poses a healthcare challenge. This study aimed to compare symptom profiles in partial PPI responders and treatment-naïve patients with gastroesophageal reflux disease (GERD).

Methods

A post hoc analysis of data from two studies was performed. Partial PPI responders with GERD (n = 580; NCT00703534) had frequent (≥ 3 days/week) heartburn and/or regurgitation despite PPI therapy; patients with no improvement were excluded. Treatment-naïve patients with GERD (diagnosed by endoscopy and pH-metry; n = 203; NCT00291746) had frequent (≥ 3 days/week) upper gastrointestinal symptoms. The Gastrointestinal Symptom Rating Scale (GSRS) was completed by all patients at study entry and by treatment-naïve patients after PPI therapy.

Results

The highest (mean [95% confidence interval]) discomfort scores were reported in the Reflux (heartburn, regurgitation), Indigestion, and Abdominal pain domains of the GSRS, both in partial PPI responders (4.3 [4.2–4.4], 3.7 [3.6–3.8], and 3.4 [3.3–3.5], respectively) and in treatment-naïve patients (3.5 [3.3–3.7], 3.6 [3.4–3.7], and 3.1 [3.0–3.3], respectively). Partial PPI responders reported more discomfort than treatment-naïve patients in the Reflux, Abdominal pain, and Constipation domains (4.3 [4.2–4.4] vs. 3.5 [3.3–3.7], 3.4 [3.3–3.5] vs. 3.1 [3.0–3.3], and 2.5 [2.4–2.6] vs. 2.1 [1.9–2.2], respectively). All GSRS domain scores improved in treatment-naïve patients following PPI therapy.

Conclusions

Symptom patterns in partial PPI responders were similar to those in treatment-naïve patients with GERD, but partial PPI responders experienced more severe reflux, abdominal pain, and constipation than did treatment-naïve patients.

【 授权许可】

   
2014 Vakil et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]El-Serag H, Becher A, Jones R: Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther 2010, 32(6):720-737.
• [2]Toghanian S, Johnson DA, Stalhammar NO, Zerbib F: Burden of gastro-oesophageal reflux disease in patients with persistent and intense symptoms despite proton pump inhibitor therapy: a post hoc analysis of the 2007 national health and wellness survey. Clin Drug Investig 2011, 31(10):703-715.
• [3]Fass R, Shapiro M, Dekel R, Sewell J: Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease – where next? Aliment Pharmacol Ther 2005, 22(2):79-94.
• [4]Boeckxstaens GE, Smout A: Systematic review: role of acid, weakly acidic and weakly alkaline reflux in gastroesophageal reflux disease. Aliment Pharmacol Ther 2010, 32(3):334-343.
• [5]Neumann H, Monkemuller K, Kandulski A, Malfertheiner P: Dyspepsia and IBS symptoms in patients with NERD, ERD and Barrett’s esophagus. Dig Dis 2008, 26(3):243-247.
• [6]Gerson LB, Kahrilas PJ, Fass R: Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastroenterol Hepatol 2011, 9(10):824-833.
• [7]Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R: The Montreal definition and classification of gastro-esophageal reflux disease (GERD) – a global evidence-based consensus. Am J Gastroenterol 2006, 101(8):1900-1920.
• [8]Vakil N, Halling K, Ohlsson L, Wernersson B: Symptom overlap between postprandial distress and epigastric pain syndromes of the Rome III dyspepsia classification. Am J Gastroenterol 2013, 108(5):767-774.
• [9]Quigley EM, Lacy BE: Overlap of functional dyspepsia and GERD–diagnostic and treatment implications. Nat Rev Gastroenterol Hepatol 2013, 10(3):175-186.
• [10]de Bortoli N, Martinucci I, Bellini M, Savarino E, Savarino V, Blandizzi C, Marchi S: Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. World J Gastroenterol 2013, 19(35):5787-5797.
• [11]Savarino E, Pohl D, Zentilin P, Dulbecco P, Sammito G, Sconfienza L, Vigneri S, Camerini G, Tutuian R, Savarino V: Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut 2009, 58(9):1185-1191.
• [12]Vakil N, Björck K, Denison H, Halling K, Karlsson M, Paty J, Silberg D, Rydén A: Validation of the Reflux Symptom Questionnaire electronic Diary in partial responders to proton pump inhibitor therapy. Clin Trans Gastroenterol 2012, 3:e7.
• [13]Dent J, Vakil N, Jones R, Bytzer P, Schoning U, Halling K, Junghard O, Lind T: Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010, 59(6):714-721.
• [14]Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I: Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol 1995, 30(11):1046-1052.
• [15]Talley NJ, Fullerton S, Junghard O, Wiklund I: Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. Am J Gastroenterol 2001, 96(7):1998-2004.
• [16]Juniper EF, Guyatt GH, Willan A, Griffith LE: Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994, 47(1):81-87.
• [17]Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS: Interpreting treatment effects in randomised trials. BMJ 1998, 316(7132):690-693.
• [18]Zerbib F, Duriez A, Roman S, Capdepont M, Mion F: Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors. Gut 2008, 57(2):156-160.
• [19]Dickman R, Boaz M, Aizic S, Beniashvili Z, Fass R, Niv Y: Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil 2011, 17(4):387-394.
• [20]Zerbib F, Belhocine K, Simon M, Capdepont M, Mion F, Bruley des Varannes S, Galmiche JP: Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012, 61(4):501-506.
• [21]Du J, Liu J, Zhang H, Yu CH, Li YM: Risk factors for gastroesophageal reflux disease, reflux esophagitis and non-erosive reflux disease among Chinese patients undergoing upper gastrointestinal endoscopic examination. World J Gastroenterol 2007, 13(45):6009-6015.
• [22]Fass R, Sifrim D: Management of heartburn not responding to proton pump inhibitors. Gut 2009, 58:295-309.
• [23]Sifrim D, Zerbib F: Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012, 61(9):1340-1354.
• [24]Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D: Arbaclofen placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011, 106(8):1427-1438.
• [25]Shaheen NJ, Denison H, Bjorck K, Karlsson M, Silberg DG: Efficacy and safety of lesogaberan in gastro-oesophageal reflux disease: a randomised controlled trial. Gut 2013, 62(9):1248-1255.
• [26]Vakil NB, Huff FJ, Cundy KC: Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease–insights into study design for transient lower sphincter relaxation inhibitors. Aliment Pharmacol Ther 2013, 38(2):107-117.